Altre lingue Artelo Biosciences, Inc.

Azioni

ARTL

US04301G5080

Mercato chiuso - Nasdaq Altri mercati azionari 22:30:00 17/06/2024			Variaz. 5gg	Var. 1 gen.
1,325 ^USD	-3,28%		-2,93%	-5,36%

13/05	Artelo Biosciences, Inc. riporta i risultati degli utili per il primo trimestre conclusosi il 31 marzo 2024	CI
23/04	Transcript : Artelo Biosciences, Inc. - Special Call

Altre lingue

Sblocca tutte le notizie: sii il primo a essere informato e reagisci prima dei mercati!

Registrazione 100% gratuita

Artelo Biosciences Presents Important New Data on ART26.12 at the 57th Annual Scientific Meeting of the British Pain Society	04/06
Artelo Biosciences Presents Highly Encouraging Data Towards Developing a Solid Dosage Form of ART12.11 at CT-CANN24	29/05
Artelo Biosciences to Present at the Pharma Partnering Summit 2024 on May 14th	13/05
Artelo Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	13/05
Artelo Biosciences Reports First Quarter 2024 Financial Results and Provides Business Update	13/05
Artelo Biosciences to Present at the Pharma Partnering Summit 2024 on May 14th	10/05
Artelo Biosciences Announces Publication of Peer-Reviewed Article Highlighting FABP7 as a Promising Novel Target in Cancer Therapy	23/04
Artelo Biosciences, Inc. Announces Publication of Peer-Reviewed Article Highlighting FABP7 as a Promising Novel Target in Cancer Therapy	23/04
Artelo Biosciences CEO to Appear on Benzinga All Access on April 23rd at Approximately 10:50 AM Eastern Time	22/04
Artelo Biosciences Reports Fiscal 2023 Year-End Financial Results and Provides Business Update	25/03
Artelo Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	25/03
Artelo Biosciences Selected as a Finalist in Johnson & Johnson’s Innovation Challenge	12/03
Top Premarket Gainers	06/02
Artelo Biosciences Announces Publication of New Peer-Reviewed Pre-Clinical Research Demonstrating ART26.12’s Effectiveness in Treating and Preventing Oxaliplatin-Induced Peripheral Neuropathy	23/01
Artelo Biosciences, Inc. Announces Publication of New Peer-Reviewed Pre-Clinical Research Demonstrating ART26.12's Effectiveness in Treating and Preventing Oxaliplatin-Induced Peripheral Neuropathy	23/01
Artelo Biosciences Announces Selection of Worldwide Clinical Trials as Clinical Research Organization to Support First-in-Human Study of ART26.12	08/01
Artelo Biosciences Presents New Preclinical Data on ART12.11 at the 4th Annual Med-Cannabis 2023 Conference in Germany	05/12
Artelo Biosciences to Present Important New Preclinical Data on ART12.11 at the 4th Annual Med-Cannabis 2023 Conference in Germany	30/11
Artelo Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	13/11
Artelo Biosciences Reports Third Quarter 2023 Financial Results and Provides Business Update	13/11

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Artelo Biosciences, Inc.

Azioni

ARTL

US04301G5080

Altre lingue

Filtri